Histopathology

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

Retrieved on: 
Friday, January 12, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Histopathology, Weight loss, Gynaecology, Bevacizumab, Cisplatin, Hypothyroidism, University, Cancer, Risk, COVID-19, Diarrhea, Hyperthyroidism, Brachytherapy, Neoplasm, Perforated ulcer, Hepatitis, FIGO, CRT, Pyelonephritis, Colitis, Vagina, ClinicalTrials.gov, PD-L1, RECIST, Disease, Patient, Fever, CPS, Chemoradiotherapy, Vomiting, MRK, Death, Nephritis, Progression-free survival, OS, Radiation, Anemia, Survival, EBRT, Abdominal pain, Intraparenchymal hemorrhage, Uterus, Cervical cancer, Constipation, PFS, Fatal, Obstetrics, Hematopoietic stem cell transplantation, Pneumonitis, Nausea, Pelvic pain, Dysuria, Fatigue, GOG, Arm, Rash, Food, Merck & Co., Sepsis, Toxicity, News, Urinary tract infection, Appetite, Pharmaceutical industry

Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

Key Points: 
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • “Building on the established role of KEYTRUDA in advanced cervical cancer, KEYTRUDA plus chemoradiotherapy is now the first anti-PD-1-based regimen approved in the U.S. for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer regardless of PD-L1 expression,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.
  • The trial enrolled 1,060 patients with cervical cancer who had not previously received any definitive surgery, radiation, or systemic therapy for cervical cancer.
  • In the exploratory subgroup analysis of 596 patients with FIGO 2014 Stage III-IVA disease, 61 patients (21%) in the KEYTRUDA plus CRT arm (n=293) experienced a PFS event versus 94 patients (31%) in the placebo plus CRT arm (n=303).

Vesigen Highlights Non-Human Primate Biodistribution of Non-Viral Technology and Functional Delivery of Genome Editors In Vivo at the Cracking the Code: The Dawn of Nucleic Acid Medicines Meeting

Retrieved on: 
Thursday, October 19, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Gene editing, Retinal pigment epithelium, Mouse, Dawn, RNA, ARMM, Histopathology, ARMM Regional Legislative Assembly, RPE, Disease, Cell death, Cytotoxicity, Therapy, Kupffer cell, Retina, Vaccine

Specifically, the Company presented new data demonstrating retinal biodistribution of engineered ARMMs across multiple species – including non-human primates – and data demonstrating successful in vivo functional delivery of a Cas9/guide RNA gene editing complex.

Key Points: 
  • Specifically, the Company presented new data demonstrating retinal biodistribution of engineered ARMMs across multiple species – including non-human primates – and data demonstrating successful in vivo functional delivery of a Cas9/guide RNA gene editing complex.
  • The data were presented at the Cracking the Code: The Dawn of Nucleic Acid Medicines meeting, taking place October 17-19, 2023, in Worcester, MA.
  • “We have shown that our ARMM technology can successfully deliver functionally active gene editing complexes to Kupffer cells and ameliorate disease in an acute liver injury model.
  • Additional data in mice, minipigs, and non-human primates demonstrated the efficient delivery of subretinally administered ARMMs to the RPE and photoreceptors, cell types associated with multiple retinal diseases.

Rubedo Life Sciences Announces Nomination of First-in-Class Disease-Modifying Candidate RLS-1496 in Dermatology at LSX World Congress 2023

Retrieved on: 
Wednesday, May 3, 2023
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Tissue, Drug discovery, Pathology, Histopathology, Atopic dermatitis, Multimedia, Inflammation, RNA, Dermatitis, Psoriasis, Dermatology, Standard of care, Patient, Machine learning, LSX, Rubedo, SVP, IND, Conference, Skin, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20230503005464/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230503005464/en/
    Marco Quarta, Ph.D., CEO & Co-Founder, Rubedo Life Sciences presenting at LSX World Conference 2023.
  • (Photo: Business Wire)
    RLS-1496 is a disease-modifying therapy with the potential for superiority over standard of care in multiple chronic skin indications.
  • Rubedo’s R&D program in dermatology was initiated in Q4 2021, and effective progression from target discovery to candidate nomination took one and a half years.
  • ALEMBIC™ Senescence Signatures were utilized to analyze skin samples derived from patients with chronic dermatological conditions, such as dermatitis and psoriasis.

Rubedo Life Sciences Presents In Vivo Efficacy Data Targeting Senescence Cells to Treat Dermatological Diseases

Retrieved on: 
Monday, March 20, 2023
Research, Other Health, Pharmaceutical, Oncology, Consumer, Genetics, Clinical Trials, Science, Biotechnology, Stem Cells, Seniors, Health, Other Science, Senior, Drug discovery, Department of Medicine – University of Pamplona, Histopathology, Ageing, Coronavirus Scientific Advisory Board, American Academy, Multimedia, Dermatitis, Cell, Inflammation, Psoriasis, Hair, Dermatology, Professor, Physician, AAD, Memorial Sloan Kettering Cancer Center, Rubedo, Pharmaceutical industry, Management, Vaccine

Rubedo Life Sciences , a biopharmaceutical company committed to developing first-in-class disease-modifying therapies for chronic age-related diseases, presented to key opinion leaders in vivo efficacy data for its small molecule therapy targeting senescent cells that drive cellular aging to treat dermatological diseases.

Key Points: 
  • Rubedo Life Sciences , a biopharmaceutical company committed to developing first-in-class disease-modifying therapies for chronic age-related diseases, presented to key opinion leaders in vivo efficacy data for its small molecule therapy targeting senescent cells that drive cellular aging to treat dermatological diseases.
  • The focus of the annual conference is to help dermatological professionals learn about the latest industry updates and research.
  • View the full release here: https://www.businesswire.com/news/home/20230320005208/en/
    Ofir Moreno, Ph.D., is Senior Vice President, Drug Discovery at Rubedo, presenting at the OncoDermatology Society conference.
  • Leveraging its proprietary single-cell multiomics platform ALEMBIC™, Rubedo identifies pathologic cells with senescence features characteristic of multiple dermatological chronic skin conditions, and is developing potent and selective compounds targeting those cells using its selective senolytic platform SenTech™.

OptraSCAN launches OnDemand Digital Pathology

Retrieved on: 
Tuesday, March 14, 2023
Cloud, USCAP, Annual general meeting, AI, Brightfield, Temple of Azure Clouds, Hospital, Histopathology, IHC, Pathology, Laboratory, SAN, Digital, Microsoft, Capital, Fluorescence, Television, Telepathology

SAN JOSE, Calif., March 14, 2023 /PRNewswire/ -- OptraSCAN®, the leading end-to-end digital pathology solution provider announces the introduction of OnDemand Digital Pathology® solution to meet today's need for complete digital transformation of pathology laboratories in North America. Laboratories and Hospitals can save hundreds of thousands of dollars spent on Capital purchases by subscribing to OptraSCAN OnDemand Digital Pathology® for a low monthly fee.

Key Points: 
  • SAN JOSE, Calif., March 14, 2023 /PRNewswire/ -- OptraSCAN®, the leading end-to-end digital pathology solution provider announces the introduction of OnDemand Digital Pathology® solution to meet today's need for complete digital transformation of pathology laboratories in North America.
  • Laboratories and Hospitals can save hundreds of thousands of dollars spent on Capital purchases by subscribing to OptraSCAN OnDemand Digital Pathology® for a low monthly fee.
  • OptraSCAN OnDemand Digital Pathology® subscription service will offer OptraSCAN whole slide digital scanners (Brightfield / Fluorescence) with 15-480 slide loading capacity, scanning in about 58 seconds at 40x, a high-end workstation pre-loaded with workflow software, a Telepathology application, and AI analytics packages for IHC / Morphology / Immunofluorescence and Cytology, plus Microsoft Azure Cloud storage and 24x7 support and services.
  • Speaking at the United States and Canadian Academy of Pathologists (USCAP) Annual Meeting in New Orleans, (Booth #404), Abhi Gholap, Founder and CEO, OptraSCAN said, "Pathology is a cost-conscious market and the current requirement to invest $300-$500k to adopt digital pathology has limited its adoption over the last two decades.

CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results

Retrieved on: 
Wednesday, February 15, 2023
Research, Surgery, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Completeness, American Society of Clinical Oncology, Immunotherapy, Abstract, Biologics license application, Corporation, NYSE, Head, Radiation, Patient, European Society of Gynaecological Oncology, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Sale, Harvard Medical School, Food, Survival, Marketing, Public health, Faculty, Society, Neoplasm, ESMO, SCC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Publishing, European Society for Medical Oncology, Depreciation, BLA, Histopathology, ASCO, Pharmaceutical industry, Dentistry, Generic drug

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2022, as well as key clinical and corporate developments.

Key Points: 
  • CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2022, as well as key clinical and corporate developments.
  • These data, from CEL-SCI’s Phase 3 head and neck cancer study, were presented by Dr. Philip Lavin in a video that was made public in October 2022.
  • Dr. Lavin is a well-known biostatistician with a long history of supporting clinical trials for product registrations, reimbursements, and public health advancement.
  • The presentation and images can be seen here: LINK
    During the fiscal 2023 first quarter, CEL-SCI focused on assembling the vast body of clinical documentation of a Biologic License Application (BLA) required to obtain FDA approval for commercial marketing of Multikine.

TransMed7, LLC Announces First Clinical Use of Heron Soft Tissue Biopsy Devices for Commercial Launch

Retrieved on: 
Tuesday, August 16, 2022
Biotechnology, Surgery, Medical Devices, Health, Oncology, FDA, Liver, Cardiovascular disease, Cardiovascular and Interventional Radiological Society of Europe, BPH, RSNA, CEO, College of Medicine, Diagnosis, Breast, Technology, Heron, Clinical, Needle, WCU, Regenerative medicine, XPK, LLC, Federal Food, Drug, and Cosmetic Act, Atlantic Film Festival, Patient, Prostate, Lymph, Globe, Skin, Architecture, RO, XP, Radiological Society of North America, Kidney, Histopathology, Phoenix, Arizona, Physician, XPS, Lung, University, McKesson Corporation, Solution, Blood, Neuro, RCU, Biopsy, Medicine, Medical imaging, Medical device

The whole biopsy procedure was finished in less than 5 minutes, which represents a significant cost savings as well.

Key Points: 
  • The whole biopsy procedure was finished in less than 5 minutes, which represents a significant cost savings as well.
  • The Heron platform of soft tissue biopsy devices includes three models of hand-held, ultrasound guided, vacuum assisted, full fluid management, SIMC devices.
  • The Heron XPK and XPS full featured models are designed for manual coring length control and automatic tissue transport.
  • The Heron platform devices will provide the most advanced capabilities for biopsy devices featuring needle sizes from 12 to 18 gauge.

Updated Preclinical Data Support Potential of First AAV-Based Gene Therapy as a Treatment for Adrenomyeloneuropathy

Retrieved on: 
Tuesday, April 5, 2022
Biotechnology, General Health, Health, Genetics, Clinical Trials, Spinal cord, Cell, Therapy, ESGCT, AMN, Poster, Hereditary spastic paraplegia, Mass, Gene expression, Adrenoleukodystrophy, American Academy of Neurology, Vance DeGeneres, Clinical trial, AAV, Incontinence, Toxicology, Pharmacology, White matter, European Society of Gene and Cell Therapy, Man, Tissue, Pain, Sexual dysfunction, Quality of life, Safety, Annual general meeting, Intrathecal administration, DRG, Mutation, American Academy, Primate, AAN, Gene, FDA, Patient, Disease, Histopathology, Pharmaceutical industry, Dietary supplement, Medical device, Vaccine, ABCD1

These data support the potential of SBT101 as a treatment for adrenomyeloneuropathy (AMN), a progressive, inherited, and debilitating neurodegenerative disease caused by a deficiency in the ABCD1 gene which primarily affects the spinal cord.

Key Points: 
  • These data support the potential of SBT101 as a treatment for adrenomyeloneuropathy (AMN), a progressive, inherited, and debilitating neurodegenerative disease caused by a deficiency in the ABCD1 gene which primarily affects the spinal cord.
  • SwanBio will present additional data during the AAN virtual meeting April 24-26, 2022.
  • These data represent the tremendous progress weve made to date on our pipeline and scientific platform.
  • SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, inherited neurological conditions.

Castle Biosciences Presents Data from Suite of Dermatologic Cancer Genomic Tests at Fall Clinical Dermatology Conference 2021

Retrieved on: 
Friday, October 22, 2021
Oncology, Health, Genetics, Research, Science, Biotechnology, Gene, Disease, Psoriasis, Dermatology, Skin, History, SCC, Atopic dermatitis, Lymph node, Trial of the century, COVID-19, Health, National Comprehensive Cancer Network, Drug Quality and Security Act, Acquisition, Publication, Securities Exchange Act of 1934, Death, Research, Quality of life, Diagnosis, GEP, Survival, RNA, Company, List of life sciences, MSS, IRB, Gene expression, Physician, Workflow, SEC, Risk, SLN, RFS, Malignancy, Â, Nasdaq, Melanoma, Baylor University Medical Center, Population, DecisionDx-UM, CDO, Recurrence, Securities Act of 1933, Poster, Metastasis, Algorithm, NCCN, Patient, Sentinel lymph node, Time, Conference, Adult, Disease management, Histopathology, Uveal melanoma, Uncertainty, Medical device, Medical imaging, Cryptocurrency, Silviculture, Health insurance, Vaccine, Pharmaceutical industry, DecisionDx-Melanoma, Castle Biosciences’ Comprehensive Diagnostic Offering for Difficult-to-Diagnose Melanocytic Lesions, Psoriasis, Atopic Dermatitis and Related Conditions, DecisionDx-SCC, Castle Biosciences, DECISIONDX-MELANOMA, CASTLE BIOSCIENCES’ COMPREHENSIVE DIAGNOSTIC OFFERING FOR DIFFICULT-TO-DIAGNOSE MELANOCYTIC LESIONS, PSORIASIS, ATOPIC DERMATITIS AND RELATED CONDITIONS, DECISIONDX-SCC, CASTLE BIOSCIENCES

The i31-SLNB algorithm identified 31.2% (135/433) of patients with a

Key Points: 
  • The i31-SLNB algorithm identified 31.2% (135/433) of patients with a
  • This study highlighted the results of all CDO clinical cases submitted to Castle Biosciences between June 30-Aug. 31, 2021.
  • Only 1.1% of cases received an intermediate result from both tests; the technical failure rate of both tests combined was 0.2%.
  • Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic diagnostics company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions.

Veru to Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call on August 12th

Retrieved on: 
Thursday, July 29, 2021
Cancer, Histopathology, Prostate cancer, Breast cancer, Oncology, Management of prostate cancer

Verus management will host a conference call that same day at 8 a.m.

Key Points: 
  • Verus management will host a conference call that same day at 8 a.m.
  • Interested parties may access the call by dialing 800-341-1602 from the U.S. or 412-902-6706 from outside the U.S. and asking to be joined into the Veru Inc. call.
  • The call will also be available through a live, listen-only audio broadcast via the Internet at www.verupharma.com.
  • Veru Inc.is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer.